Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
26 03 2021
Historique:
received: 22 07 2020
accepted: 25 02 2021
entrez: 27 3 2021
pubmed: 28 3 2021
medline: 13 4 2021
Statut: epublish

Résumé

In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1

Identifiants

pubmed: 33772027
doi: 10.1038/s41467-021-22115-1
pii: 10.1038/s41467-021-22115-1
pmc: PMC7997928
doi:

Substances chimiques

CSDE1 protein, human 0
Cancer Vaccines 0
DNA-Binding Proteins 0
RNA-Binding Proteins 0
Interferon-beta 77238-31-4

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1930

Subventions

Organisme : NCI NIH HHS
ID : P50 CA210964
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI132165
Pays : United States

Références

Gene Ther. 2006 Jan;13(2):138-49
pubmed: 16136162
Hum Gene Ther. 2010 Apr;21(4):439-50
pubmed: 19922169
Nat Biotechnol. 2012 Mar 18;30(4):337-43
pubmed: 22426030
Mol Ther. 2009 Oct;17(10):1814-21
pubmed: 19603003
Nature. 2013 Feb 21;494(7437):366-70
pubmed: 23389445
Mol Ther. 2017 Apr 5;25(4):962-975
pubmed: 28237836
Mol Ther. 2007 Nov;15(11):2044-50
pubmed: 17726460
Mol Ther. 2017 Aug 2;25(8):1917-1932
pubmed: 28578991
Nat Genet. 2013 Sep;45(9):970-6
pubmed: 23852170
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
J Virol. 2013 May;87(9):4808-17
pubmed: 23449789
Mol Ther. 2011 Jan;19(1):150-8
pubmed: 20959810
Semin Immunol. 2020 Feb;47:101395
pubmed: 32205022
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
J Virol. 2003 Aug;77(16):8843-56
pubmed: 12885903
Hum Gene Ther. 2010 Apr;21(4):451-62
pubmed: 19911974
Int J Cancer. 2012 Aug 15;131(4):844-54
pubmed: 21935923
Nat Commun. 2017 Nov 13;8(1):1456
pubmed: 29129916
Nat Med. 2013 Dec;19(12):1625-1631
pubmed: 24240185
Cancer Res. 2009 Oct 1;69(19):7713-20
pubmed: 19773437
Mol Ther. 2011 Jan;19(1):140-9
pubmed: 20978474
Nucleic Acids Res. 1999 Apr 15;27(8):1926-34
pubmed: 10101203
Bioessays. 2010 Feb;32(2):109-18
pubmed: 20091748
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Nat Commun. 2020 Feb 7;11(1):790
pubmed: 32034147
Virus Res. 2018 Apr 2;249:52-56
pubmed: 29545014
J Clin Med. 2019 Apr 25;8(4):
pubmed: 31027221
Cancer Res. 2010 Jun 1;70(11):4539-49
pubmed: 20484025
Nat Rev Immunol. 2004 Nov;4(11):868-77
pubmed: 15516966
Hum Gene Ther. 2011 Nov;22(11):1343-53
pubmed: 21366404
Br J Cancer. 2005 Apr 25;92(8):1450-8
pubmed: 15812550
Sci Adv. 2016 Oct 07;2(10):e1601737
pubmed: 27730215
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
Mol Biol Evol. 2005 Feb;22(2):367-77
pubmed: 15496550
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28710258
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Cancer Immunol Res. 2017 Nov;5(11):1029-1045
pubmed: 29038298
Pigment Cell Melanoma Res. 2008 Apr;21(2):147-61
pubmed: 18426408
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Cancer Cell. 2003 Oct;4(4):263-75
pubmed: 14585354
Front Immunol. 2020 Apr 28;11:683
pubmed: 32411132
J Gen Virol. 2007 Nov;88(Pt 11):3043-3052
pubmed: 17947529
Ann Oncol. 2018 Mar 1;29(3):563-572
pubmed: 29324969
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2841-6
pubmed: 25730878
Mol Ther Oncolytics. 2018 Aug 29;11:1-13
pubmed: 30294666
Mol Ther. 2014 Nov;22(11):1936-48
pubmed: 25059678
JAMA Oncol. 2019 Jan 1;5(1):96-103
pubmed: 30098166
Nat Med. 2000 Jul;6(7):821-5
pubmed: 10888934
Mol Ther. 2014 Jun;22(6):1198-1210
pubmed: 24590047
Cancer Immunol Res. 2019 May;7(5):828-840
pubmed: 30940643
Cancer Cell. 2019 Sep 16;36(3):337
pubmed: 31526761
Cancer Res. 2007 Mar 15;67(6):2840-8
pubmed: 17363607
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Genes (Basel). 2017 Jan 22;8(1):
pubmed: 28117753
Gene Ther. 2010 Feb;17(2):158-70
pubmed: 20016540
Curr Oncol. 2020 Apr;27(Suppl 2):S98-S105
pubmed: 32368179
Cell Commun Signal. 2020 Jan 27;18(1):14
pubmed: 31987048
Mol Ther. 2013 Aug;21(8):1507-16
pubmed: 23752316
J Virol. 2003 Mar;77(6):3353-9
pubmed: 12610110
J Exp Med. 1998 Jul 20;188(2):277-86
pubmed: 9670040
Nat Med. 2011 Jun 19;17(7):854-9
pubmed: 21685898
Mol Ther. 2015 May;23(5):845-856
pubmed: 25544599
Gene Ther. 2017 Jan;24(1):21-30
pubmed: 27779616

Auteurs

Timothy Kottke (T)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Jason Tonne (J)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Laura Evgin (L)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Christopher B Driscoll (CB)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Jacob van Vloten (J)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Victoria A Jennings (VA)

Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Amanda L Huff (AL)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Brady Zell (B)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Jill M Thompson (JM)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Phonphimon Wongthida (P)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Jose Pulido (J)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Matthew R Schuelke (MR)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

Adel Samson (A)

Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Peter Selby (P)

Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Elizabeth Ilett (E)

Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Mark McNiven (M)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Lewis R Roberts (LR)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Mitesh J Borad (MJ)

Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.

Hardev Pandha (H)

Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Kevin Harrington (K)

Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.

Alan Melcher (A)

Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.

Richard G Vile (RG)

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. vile.richard@mayo.edu.
Leeds Institute of Medical Research, University of Leeds, Leeds, UK. vile.richard@mayo.edu.
Department of Immunology, Mayo Clinic, Rochester, MN, USA. vile.richard@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH